Edgewise Therapeutics, Inc. Common Stock (EWTX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 154
- Market Cap
- $4.4B
About Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
SentiSense also tracks daily options readings for Edgewise Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Edgewise Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.